RAF1 gene fusions are recurrent driver events in infantile fibrosarcoma-like mesenchymal tumors.
MAPK signaling
PI3K‐AKT signaling
RAF kinase
fusion proteins
infantile fibrosarcoma
Journal
The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634
Informations de publication
Date de publication:
17 Apr 2024
17 Apr 2024
Historique:
revised:
21
12
2023
received:
08
11
2023
accepted:
13
02
2024
medline:
17
4
2024
pubmed:
17
4
2024
entrez:
17
4
2024
Statut:
aheadofprint
Résumé
Infantile fibrosarcomas (IFS) and congenital mesoblastic nephroma (CMN) are rare myofibroblastic tumors of infancy and early childhood commonly harboring the ETV6::NTRK3 gene fusion. IFS/CMN are considered as tumors with an 'intermediate prognosis' as they are locally aggressive, but rarely metastasize, and generally have a favorable outcome. A fraction of IFS/CMN-related neoplasms are negative for the ETV6::NTRK3 gene rearrangement and are characterized by other chimeric proteins promoting MAPK signaling upregulation. In a large proportion of these tumors, which are classified as IFS-like mesenchymal neoplasms, the contributing molecular events remain to be identified. Here, we report three distinct rearrangements involving RAF1 among eight ETV6::NTRK3 gene fusion-negative tumors with an original histological diagnosis of IFS/CMN. The three fusion proteins retain the entire catalytic domain of the kinase. Two chimeric products, GOLGA4::RAF1 and LRRFIP2::RAF1, had previously been reported as driver events in different cancers, whereas the third, CLIP1::RAF1, represents a novel fusion protein. We demonstrate that CLIP1::RAF1 acts as a bona fide oncoprotein promoting cell proliferation and migration through constitutive upregulation of MAPK signaling. We show that the CLIP1::RAF1 hyperactive behavior does not require RAS activation and is mediated by constitutive 14-3-3 protein-independent dimerization of the chimeric protein. As previously reported for the ETV6::NTRK3 fusion protein, CLIP1::RAF1 similarly upregulates PI3K-AKT signaling. Our findings document that RAF1 gene rearrangements represent a recurrent event in ETV6::NTRK3-negative IFS/CMN and provide a rationale for the use of inhibitors directed to suppress MAPK and PI3K-AKT signaling in these cancers. © 2024 The Pathological Society of Great Britain and Ireland.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 28768
Organisme : Ministero della Salute
Informations de copyright
© 2024 The Pathological Society of Great Britain and Ireland.
Références
Coffin CM, Alaggio R. Fibroblastic and myofibroblastic tumors in children and adolescents. Pediatr Dev Pathol 2012; 15: 127–180.
Sultan I, Casanova M, Al‐Jumaily U, et al. Soft tissue sarcomas in the first year of life. Eur J Cancer 2010; 46: 2449–2456.
Knezevich SR, McFadden DE, Tao W, et al. A novel ETV6‐NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998; 18: 184–187.
Pavlick D, Schrock AB, Malicki D, et al. Identification of NTRK fusions in pediatric mesenchymal tumors. Pediatr Blood Cancer 2017; 64: e26433.
Tognon C, Garnett M, Kenward E, et al. The chimeric protein tyrosine kinase ETV6‐NTRK3 requires both Ras‐Erk1/2 and PI3‐kinase‐Akt signaling for fibroblast transformation. Cancer Res 2001; 61: 8909–8916.
Davis JL, Al‐Ibraheemi A, Rudzinski ER, et al. Mesenchymal neoplasms with NTRK and other kinase gene alterations. Histopathology 2022; 80: 4–18.
Kojima N, Mori T, Motoi T, et al. Frequent CD30 expression in an emerging group of mesenchymal tumors with NTRK, BRAF, RAF1, or RET fusions. Mod Pathol 2023; 36: 100083.
Warmke LM, Al‐Ibraheemi A, Wang L, et al. FGFR1 gene fusions in a subset of pediatric mesenchymal tumors: expanding the genetic spectrum of tumors sharing histologic overlap with infantile fibrosarcoma and ‘NTRK‐rearranged’ spindle cell neoplasms. Genes Chromosomes Cancer 2023; 62: 641–647.
Pfister SM, Reyes‐Múgica M, Chan JKC, et al. A summary of the inaugural WHO classification of pediatric tumors: transitioning from the optical into the molecular era. Cancer Discov 2022; 12: 331–355.
Penning AJ, Al‐Ibraheemi A, Michal M, et al. Novel BRAF gene fusions and activating point mutations in spindle cell sarcomas with histologic overlap with infantile fibrosarcoma. Mod Pathol 2021; 34: 1530–1540.
Suurmeijer AJH, Dickson BC, Swanson D, et al. A novel group of spindle cell tumors defined by S100 and CD34 co‐expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes. Genes Chromosomes Cancer 2018; 57: 611–621.
Coffin CM, Beadling C, Neff T, et al. Infantile fibrosarcoma with a novel RAF1 rearrangement: the contemporary challenge of reconciling classic morphology with novel molecular genetics. Hum Pathol: Case Rep 2020; 22: 200434.
Hicks JK, Henderson‐Jackson E, Duggan J, et al. Identification of a novel MTAP‐RAF1 fusion in a soft tissue sarcoma. Diagn Pathol 2018; 13: 77.
Mok Y, Kimpo MS, Chen H, et al. Spindle cell tumour with S100 and CD34 co‐expression showing PDZRN3‐RAF1 rearrangement – a recently described entity. Histopathology 2019; 74: 1109–1111.
Zhang T, Wang Q, Yi X, et al. RAF1‐rearranged spindle cell tumour: report of two additional cases with identification of a novel FMR1‐RAF1 fusion. Virchows Arch 2021; 479: 1245–1253.
Gong LH, Liu WF, Niu XH, et al. Two cases of spindle cell tumors with S100 and CD34 co‐expression showing novel RAF1 fusions. Diagn Pathol 2022; 17: 80.
Yeung MCF, Lam AYL, Shek TWH. Novel MAP4::RAF1 fusion in a primary bone sarcoma: expanding the spectrum of RAF1 fusion sarcoma. Int J Surg Pathol 2022; 30: 682–688.
Dermawan JK, DiNapoli SE, Sukhadia P, et al. Malignant undifferentiated epithelioid neoplasms with MAML2 rearrangements: a clinicopathologic study of seven cases demonstrating a heterogenous entity. Genes Chromosomes Cancer 2023; 62: 191–201.
Park E, Rawson S, Li K, et al. Architecture of autoinhibited and active BRAF‐MEK1‐14‐3‐3 complexes. Nature 2019; 575: 545–550.
Tran TH, Chan AH, Young LC, et al. KRAS interaction with RAF1 RAS‐binding domain and cysteine‐rich domain provides insights into RAS‐mediated RAF activation. Nat Commun 2021; 12: 1176.
Gibney GT, Messina JL, Fedorenko IV, et al. Paradoxical oncogenesis‐the long‐term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol 2013; 10: 390–399.
Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA‐seq aligner. Bioinformatics 2013; 29: 15–21.
Sahraeian SME, Mohiyuddin M, Sebra R, et al. Gaining comprehensive biological insight into the transcriptome by performing a broad‐spectrum RNA‐seq analysis. Nat Commun 2017; 8: 59.
Vu TN, Deng W, Trac QT, et al. A fast detection of fusion genes from paired‐end RNA‐seq data. BMC Genomics 2018; 19: 786.
Nicorici D, Satalan M, Edgren H, et al. FusionCatcher – a tool for finding somatic fusion genes in paired‐end RNA‐sequencing data. bioRxiv 2014; https://doi.org/10.1101/011650. [Not peer reviewed].
Rossi S, Barresi S, Colafati GS, et al. PATZ1‐rearranged tumors of the central nervous system: characterization of a pediatric series of seven cases. Mod Pathol 2023; 37: 100387.
Cordeddu V, Di Schiavi E, Pennacchio LA, et al. Mutation of SHOC2 promotes aberrant protein N‐myristoylation and causes Noonan‐like syndrome with loose anagen hair. Nat Genet 2009; 41: 1022–1026.
Motta M, Fasano G, Gredy S, et al. SPRED2 loss‐of‐function causes a recessive Noonan syndrome‐like phenotype. Am J Hum Genet 2021; 108: 2112–2129.
Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015; 161: 1215–1228.
Hayward NK, Wilmott JS, Waddell N, et al. Whole‐genome landscapes of major melanoma subtypes. Nature 2017; 545: 175–180.
Hartmaier RJ, Albacker LA, Chmielecki J, et al. High‐throughput genomic profiling of adult solid tumors reveals novel insights into cancer pathogenesis. Cancer Res 2017; 77: 2464–2475.
McEvoy CR, Xu H, Smith K, et al. Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4‐RAF1 fusion. J Clin Invest 2019; 129: 1940–1945.
LeBlanc RE, Lefferts JA, Baker ML, et al. Novel LRRFIP2‐RAF1 fusion identified in an acral melanoma: a review of the literature on melanocytic proliferations with RAF1 fusions and the potential therapeutic implications. J Cutan Pathol 2020; 47: 1181–1186.
Jones DTW, Kocialkowski S, Liu L, et al. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009; 28: 2119–2123.
Palanisamy N, Ateeq B, Kalyana‐Sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 2010; 16: 793–798.
Chmielecki J, Hutchinson KE, Frampton GM, et al. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. Cancer Discov 2014; 4: 1398–1405.
Punekar SR, Velcheti V, Neel BG, et al. The current state of the art and future trends in RAS‐targeted cancer therapies. Nat Rev Clin Oncol 2022; 19: 637–655.
Ehrenreiter K, Piazzolla D, Velamoor V, et al. Raf‐1 regulates rho signaling and cell migration. J Biol Chem 2005; 168: 955–964.
Tian H, Yin L, Ding K, et al. Raf1 is a prognostic factor for progression in patients with non‐small cell lung cancer after radiotherapy. Oncol Rep 2018; 39: 1966–1974.
WHO classification of Tumors. Soft Tissue and Bone Tumours. IARC: Lyon, 2020.
Ross JS, Wang K, Chmielecki J, et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer 2016; 138: 881–890.
Panet F, Jung S, Alcindor T. Sustained response to the mitogen‐activated extracellular kinase inhibitor trametinib in a spindle cell sarcoma harboring a QKI‐RAF1 gene fusion. JCO Precis Oncol 2022; 6: e2100303.
Izumi H, Matsumoto S, Liu J, et al. The CLIP1‐LTK fusion is an oncogenic driver in non‐small‐cell lung cancer. Nature 2021; 600: 319–323.
Vujanić GM, Gessler M, Ooms AHAG, et al. The UMBRELLA SIOP‐RTSG 2016 Wilms tumour pathology and molecular biology protocol. Nat Rev Urol 2018; 15: 693–701.
Terwisscha van Scheltinga CEJ, Wijnen MHWA, Martelli H, et al. In transit metastases in children, adolescents and young adults with localized rhabdomyosarcoma of the distal extremities: analysis of the EpSSG RMS 2005 study. Eur J Surg Oncol 2022; 48: 1536–1542.